NCI-H1373

The NCI-H1373 cell line is a human non-small cell lung carcinoma (NSCLC) model harboring the KRAS G12C mutation, which is frequently associated with oncogenesis in lung adenocarcinoma. This mutation results in constitutive activation of downstream signaling pathways such as the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways, driving tumor proliferation and survival. NCI-H1373 is extensively used in research to evaluate the efficacy of novel therapeutic agents targeting KRAS G12C and related oncogenic pathways.

In preclinical studies, NCI-H1373 has been employed to assess the activity of emerging KRAS G12C inhibitors such as ASP2453. This inhibitor demonstrated potent, selective, and covalent binding to the mutant KRAS protein, suppressing KRAS-mediated signaling and tumor cell proliferation in vitro. The cell line was also used in xenograft models, where ASP2453 induced significant tumor regression. This activity underscores NCI-H1373's utility in understanding the therapeutic potential and mechanisms of novel KRAS inhibitors.

Additionally, NCI-H1373 has been utilized in genome-wide CRISPR knockout screens to explore mechanisms of resistance to PARP7 inhibitors. The results revealed that loss of aryl hydrocarbon receptor (AHR) signaling is associated with resistance to PARP7 inhibition, suggesting potential combination strategies. Such studies demonstrate the cell line's role in identifying resistance pathways and optimizing targeted therapies for KRAS G12C-mutated NSCLC.

37°C, 5% CO₂, humidified atmosphere.

1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

6. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium.

7. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks; for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth.

8. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes.

Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods.

To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections.

For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen.

Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage.

At Cytion, we stand behind the quality and viability of our products. We guarantee that our cells will be viable at the start of culture for 60 days after shipment from our facilities. We assure that all materials conform to the specifications described in the Certificate of Analysis and/or Product Sheet.

For full details, please refer to our Warranty Statement.